AdAlta Ltd
Tim Oldham is an accomplished executive with extensive experience in the life sciences and healthcare sectors. Currently serving as CEO and Managing Director of AdAlta Ltd since October 2019, Tim has led innovations in antibody technology. In addition to leadership roles at Tijan Ventures and Acrux, Tim has held several non-executive director positions across companies such as Imunexus Ltd and Respiri Ltd, focusing on growth strategies and commercialization. Previous experience includes being President of Hospira Asia Pacific and CEO of Cell Therapies Pty Ltd, demonstrating a strong capability in operational effectiveness and strategic partnerships. Tim holds a PhD in Physical Chemistry from Imperial College London and a Graduate Diploma of Legal Practice from the University of Technology Sydney.
This person is not in any teams
AdAlta Ltd
AdAlta (ASX:1AD) is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease. AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.